ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens April 20, 2023
ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting April 6, 2023
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee April 3, 2023
ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update March 31, 2023
ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement February 28, 2023
ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase December 19, 2022
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement December 13, 2022
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections November 28, 2022
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 14, 2022
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections September 12, 2022
